Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Authors: Leleu-Chavain, N.; Body-Malapel, M.; Spencer, J.; Chavatte, P.; Desreumaux, P.; Millet, R.
Source: Current Medicinal Chemistry, Volume 19, Number 21, July 2012 , pp. 3457-3474(18)
Publisher: Bentham Science Publishers
Abstract:The high distribution of CB2 receptors in immune cells suggests their important role in the control of inflammation. Growing evidence offers this receptor as an attractive therapeutic target: CB2 selective agonists are able to modulate inflammation without triggering psychotropic effects. This review will summarize the literature on the implication of CB2 in inflammation and CB2 selective agonists with anti-inflammatory activity.
Keywords: CB2 agonists; CB2 receptors; Crohn’s disease; IBD; aminoalkylindoles; anti-inflammatory agents; cannabinoids; central nervous system inflammation; chronic inflammatory diseases; inflammation; ischemia/reperfusion injury; morpholines; quinolones; tricyclic pyrazoles; ulcerative colitis
Document Type: Research Article
Publication date: 2012-07-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.